NASDAQ:TARA - Protara Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.67
  • Forecasted Upside: 201.31 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$15.82
▼ -0.22 (-1.37%)
1 month | 3 months | 12 months
Get New Protara Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TARA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TARA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$47.67
▲ +201.31% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Protara Therapeutics in the last 3 months. The average price target is $47.67, with a high forecast of $50.00 and a low forecast of $43.00. The average price target represents a 201.31% upside from the last price of $15.82.
Buy
The current consensus among 3 contributing investment analysts is to buy stock in Protara Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/21/2021OppenheimerReiterated RatingBuy$43.00Medium
i
2/17/2021OppenheimerInitiated CoverageOutperform$43.00Low
i
10/19/2020CowenInitiated CoverageOutperform$50.00High
i
7/29/2020GuggenheimInitiated CoverageBuy$50.00High
i
1/22/2020LADENBURG THALM/SH SHInitiated CoverageBuy$45.00High
i
(Data available from 4/18/2016 forward)
Protara Therapeutics logo
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Read More

Today's Range

Now: $15.82
$15.38
$16.16

50 Day Range

MA: $15.99
$13.75
$17.82

52 Week Range

Now: $15.82
$12.51
$67.08

Volume

38,399 shs

Average Volume

97,093 shs

Market Capitalization

$177.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Protara Therapeutics?

The following sell-side analysts have issued reports on Protara Therapeutics in the last year: Cowen Inc, Guggenheim, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for TARA.

What is the current price target for Protara Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Protara Therapeutics in the last year. Their average twelve-month price target is $47.67, suggesting a possible upside of 201.3%. Guggenheim has the highest price target set, predicting TARA will reach $50.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $43.00 for Protara Therapeutics in the next year.
View the latest price targets for TARA.

What is the current consensus analyst rating for Protara Therapeutics?

Protara Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TARA will outperform the market and that investors should add to their positions of Protara Therapeutics.
View the latest ratings for TARA.

What other companies compete with Protara Therapeutics?

How do I contact Protara Therapeutics' investor relations team?

Protara Therapeutics' physical mailing address is 1 LITTLE WEST 12TH STREET, NEW YORK NY, 10014. The company's listed phone number is 646-844-0337 and its investor relations email address is [email protected] The official website for Protara Therapeutics is www.proteontherapeutics.com.